Business Context and Reporting Period
This Form 8-K Current Report is filed by Cytosorbents Corp (Nasdaq: CTSO) with a report date of May 31, 2019. The filing addresses the termination of a material definitive agreement regarding the company's equity offering program.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, margins, debt, or liquidity metrics. However, it discloses historical data related to the terminated sales agreement:
- Total Shares Sold: 2,094,140 shares of common stock.
- Average Selling Price: $8.72 per share.
- Net Proceeds Generated: Approximately $17,718,000.
- Commission Rate Paid: 3.0% of aggregate gross proceeds.
Material Changes
The primary material change is the termination of the Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., originally dated November 4, 2015, and amended on July 26, 2018. The Company delivered written notice of termination on May 31, 2019. The agreement is scheduled to formally terminate on June 10, 2019, ten days after notice delivery. The termination occurs without liability to either party, except for specific provisions that remain in effect.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies. The document strictly reports the administrative termination of the sales agreement. No unusual items were disclosed.
Investor Verification Checklist
- Verify the effective termination date of the sales agreement (June 10, 2019).
- Confirm the total net proceeds of $17.7 million generated under the terminated agreement.
- Review the specific provisions of the Sales Agreement that remain in full force and effect post-termination.
- Check subsequent filings for any new equity financing arrangements replacing the terminated agreement.